Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126729 | 0.85 | EPHX1 (0.47) | EPHX1EPHX2LMNAHTTKMT2A | |
| SCHEMBL12308340 | 0.85 | EPHX1 (0.47) | EPHX1EPHX2LMNAHTTKMT2A | |
| SCHEMBL13834648 | 0.84 | EPHX1 (0.47) | EPHX1EPHX2LMNAHTTKMT2A | |
| SCHEMBL1497416 | 0.81 | EPHX1 (0.50) | EPHX1EPHX2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL1032166 | 0.80 | EPHX1 (0.51) | EPHX1EPHX2KMT2ASMN1; SMN2HSD11B1 | |
| SCHEMBL17226608 | 0.80 | EPHX1 (0.51) | EPHX1EPHX2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL133014 | 0.78 | EPHX1 (0.68) | EPHX1EPHX2LMNAHTTKMT2A | |
| SCHEMBL19757636 | 0.78 | EPHX1 (0.68) | EPHX1EPHX2LMNAHTTKMT2A | |
| SCHEMBL13195554 | 0.78 | EPHX1 (0.50) | EPHX1EPHX2KMT2ASMN1; SMN2HSD11B1 | |
| SCHEMBL1406564 | 0.78 | EPHX1 (0.50) | EPHX1EPHX2KMT2ASMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | EPHX1 3863/4885EPHX2 3743/4885LMNA 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.